WuXi Biologics revenue was ¥5.61 b in FY, 2020 which is a (40.9%) year over year increase from the previous period.
WuXi Biologics revenue breakdown by geographic segment: 43.9% from PRC, 44.2% from North America, 8.0% from Europe and 4.0% from Other
|FY, 2018||FY, 2019||FY, 2017|
|Post-IND Services||1.08 b||2.15 b||569.6 m|
|Pre-IND Services||1.45 b||1.81 b||1.05 b|
|FY, 2020||FY, 2018||FY, 2019||FY, 2017|
|United States||1.28 b||900.64 m|
|Europe||446.6 m||171.66 m||311.46 m||65.31 m|
|Rest of the World||222.51 m||98.83 m||127.1 m||100.85 m|
|China||980.02 m||1.41 b||552.04 m|
|North America||2.48 b||2.14 b|
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.